ACADACADIA PHARMACEUTICALS INC

Nasdaq acadia-pharm.com


$ 15.62 $ -0.08 (-0.54 %)    

Friday, 09-Aug-2024 15:59:55 EDT
QQQ $ 450.22 $ 2.34 (0.52 %)
DIA $ 395.16 $ 0.63 (0.16 %)
SPY $ 532.81 $ 2.34 (0.44 %)
TLT $ 96.28 $ 0.94 (0.99 %)
GLD $ 224.54 $ 0.55 (0.25 %)
$ 15.63
$ 15.62 x 200
$ 15.63 x 300
-- - --
$ 14.55 - $ 32.59
3,425,082
na
2.6B
$ 0.64
$ 84.98
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2024 06-30-2024 10-Q
2 05-08-2024 03-31-2024 10-Q
3 02-28-2024 12-31-2023 10-K
4 11-02-2023 09-30-2023 10-Q
5 08-02-2023 06-30-2023 10-Q
6 05-08-2023 03-31-2023 10-Q
7 02-28-2023 12-31-2022 10-K
8 11-03-2022 09-30-2022 10-Q
9 08-08-2022 06-30-2022 10-Q
10 05-04-2022 03-31-2022 10-Q
11 03-01-2022 12-31-2021 10-K
12 11-08-2021 09-30-2021 10-Q
13 08-04-2021 06-30-2021 10-Q
14 05-06-2021 03-31-2021 10-Q
15 02-25-2021 12-31-2020 10-K
16 11-04-2020 09-30-2020 10-Q
17 08-06-2020 06-30-2020 10-Q
18 05-08-2020 03-31-2020 10-Q
19 02-27-2020 12-31-2019 10-K
20 10-31-2019 09-30-2019 10-Q
21 08-01-2019 06-30-2019 10-Q
22 05-02-2019 03-31-2019 10-Q
23 02-27-2019 12-31-2018 10-K
24 11-06-2018 09-30-2018 10-Q
25 08-08-2018 06-30-2018 10-Q
26 05-04-2018 03-31-2018 10-Q
27 02-27-2018 12-31-2017 10-K
28 11-07-2017 09-30-2017 10-Q
29 08-08-2017 06-30-2017 10-Q
30 05-09-2017 03-31-2017 10-Q
31 02-28-2017 12-31-2016 10-K
32 11-07-2016 09-30-2016 10-Q
33 08-04-2016 06-30-2016 10-Q
34 05-05-2016 03-31-2016 10-Q
35 02-29-2016 12-31-2015 10-K
36 11-05-2015 09-30-2015 10-Q
37 08-06-2015 06-30-2015 10-Q
38 05-07-2015 03-31-2015 10-Q
39 02-26-2015 12-31-2014 10-K
40 11-10-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 citigroup-maintains-buy-on-acadia-pharmaceuticals-lowers-price-target-to-23

Citigroup analyst David Hoang maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $30...

 ubs-maintains-buy-on-acadia-pharmaceuticals-lowers-price-target-to-23

UBS analyst Ashwani Verma maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $25 to ...

 hc-wainwright--co-reiterates-buy-on-acadia-pharmaceuticals-maintains-27-price-target

HC Wainwright & Co. analyst Andrew Fein reiterates ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and maintains $27 pri...

 needham-maintains-buy-on-acadia-pharmaceuticals-lowers-price-target-to-28

Needham analyst Ami Fadia maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $30 to ...

 cantor-fitzgerald-maintains-overweight-on-acadia-pharmaceuticals-lowers-price-target-to-28

Cantor Fitzgerald analyst Charles Duncan maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Overweight and lowers the pri...

 rbc-capital-maintains-outperform-on-acadia-pharmaceuticals-lowers-price-target-to-26

RBC Capital analyst Gregory Renza maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform and lowers the price targ...

 morgan-stanley-downgrades-acadia-pharmaceuticals-to-equal-weight-lowers-price-target-to-20

Morgan Stanley analyst Jeffrey Hung downgrades ACADIA Pharmaceuticals (NASDAQ:ACAD) from Overweight to Equal-Weight and lowe...

 acadia-pharmaceuticals-q2-2024-gaap-eps-020-beats-018-estimate-sales-241963m-beat-235418m-estimate

ACADIA Pharmaceuticals (NASDAQ:ACAD) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate o...

 morgan-stanley-maintains-overweight-on-acadia-pharmaceuticals-lowers-price-target-to-28

Morgan Stanley analyst Jeffrey Hung maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Overweight and lowers the price ta...

 bmo-capital-initiates-coverage-on-acadia-pharmaceuticals-with-outperform-rating-announces-price-target-of-31

BMO Capital analyst Keith Tapper initiates coverage on ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform rating and ann...

 rbc-capital-reiterates-outperform-on-acadia-pharmaceuticals-maintains-29-price-target

RBC Capital analyst Gregory Renza reiterates ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform and maintains $29 price ...

 acadia-pharmaceuticals-presents-daybue-real-world-evidence-and-additional-data-in-rett-syndrome-at-the-2024-irsf-annual-scientific-meeting

Acadia Pharmaceuticals, Inc. (NASDAQ:ACAD) today announced that interim data from the open-label real-world LOTUS™ study will b...

 after-unitedhealth-cyberattack-drug-distributor-cencora-notifies-americans-health-information-stolen-in-data-breach-in-february

Cencora reports a cyberattack exposing sensitive medical information, including patient names, addresses, birth dates, diagnose...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION